Natus Medical extends revolver to 2023, cuts amount to $150 million

By Sarah Lizee

Olympia, Wash., Aug. 11 – Natus Medical Inc. amended its revolving credit agreement on Monday to extend the maturity date to Sept. 25, 2023 from Sept. 23, 2021 and reduced the amount to $150 million from $225 million, according to an 8-K filing with the Securities and Exchange Commission.

The credit agreement is with JP Morgan Chase Bank, NA, Citibank, NA and Wells Fargo Bank, NA.

Some of the covenants were also amended.

As of Tuesday, a total of $87 million out of an available $150 million was outstanding under the amended credit agreement.

Natus is a San Carlos, Calif., provider of health-care products used for the screening, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders and balance and mobility disorders.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.